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Abstract: The use of model organisms as tools for the
investigation of human genetic variation has significantly
and rapidly advanced our understanding of the aetiolo-
gies underlying hereditary traits. However, while equiva-
lences in the DNA sequence of two species may be readily
inferred through evolutionary models, the identification
of equivalence in the phenotypic consequences resulting
from comparable genetic variation is far from straightfor-
ward, limiting the value of the modelling paradigm. In this
review, we provide an overview of the emerging statistical
and computational approaches to objectively identify
phenotypic equivalence between human and model
organisms with examples from the vertebrate models,
mouse and zebrafish. Firstly, we discuss enrichment
approaches, which deem the most frequent phenotype
among the orthologues of a set of genes associated with
a common human phenotype as the orthologous
phenotype, or phenolog, in the model species. Secondly,
we introduce and discuss computational reasoning
approaches to identify phenotypic equivalences made
possible through the development of intra- and interspe-
cies ontologies. Finally, we consider the particular
challenges involved in modelling neuropsychiatric disor-
ders, which illustrate many of the remaining difficulties in
developing comprehensive and unequivocal interspecies
phenotype mappings.
Introduction
Given a candidate gene mutation thought to underlie a human
phenotype, a question commonly asked by human geneticists
investigating this candidacy is, ‘‘Does a mutation in this gene have
a comparable effect in another species?’’ To answer this, animal
models have either been made or identified that possess a genetic
aetiology relevant to a human disorder. These models have proved
themselves incredibly useful by (i) allowing repeated observations
of pathologies germane to often-rare, human genetic disorders
within an environmentally and genetically controlled background;
(ii) enabling observations of early stages of a disorder that are often
presymptomatic in humans; (iii) offering access to tissues not
normally available from human patients; and (iv) providing a
platform for therapeutic development and testing.
For many decades, the study in a model organism of the
equivalent gene, or orthologue, of a gene associated with human
phenotypic traits has delivered enormous gains in understanding
[1]. Animal models carrying null mutations, or knock-outs, in the
orthologues of human Mendelian disease genes have rapidly
advanced our understanding of this particular class of genetic
disorders, while directed mutagenesis techniques have similarly
advanced our understanding of penetrant gain-of-function
mutations. The ready-made, often-systematic availability of
animals carrying a wide range of determined disruptions has
enabled more resources to be focused on the analysis of the model
rather than its generation, and projects such as the International
Mouse Phenotyping Consortium are promising to revolutionise
our understanding of the molecular basis of human disease by
providing systematic and standardised analyses of the phenotypic
relevance of nearly all mouse genes [2–8].
With the availability of ever more phenotype data from model
organisms, the issue of what computational and algorithmic
resources will be required to make optimal use of the data is
becoming progressively more pressing. In this review, we will
discuss how phenotypes can be mapped between humans and
model species and provide a selective overview of successful
approaches to cross-species phenotype mapping. Finally, we will
focus on the area of neurobehavioral phenotypes, which is perhaps
the most difficult of all classes of phenotypes to map between
species and is representative of the challenges that remain for
comprehensive cross-species mapping.
What Is a Phenotype?
In biology, a widely accepted definition of phenotype is, ‘‘The
observable traits of an organism.’’ In medical contexts, however,
the word ‘‘phenotype’’ is more often used to refer to some
deviation from normal morphology, physiology, or behaviour, and
this is the definition that we will use here. Thus, physicians
characterise the phenotype of their patients (although they rarely
speak of it in this way) by taking a medical history or by means of a
physical examination, diagnostic imaging, blood tests, psycholog-
ical testing, and so on, in order to make the diagnosis [9].
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In some contexts, the word ‘‘phenotype’’ is commonly used to
refer to a disease entity. However, it is important to distinguish
between diseases and phenotypic features. A disease usually has
multiple phenotypic features; e.g., the disease ‘‘common cold’’ can
have the features ‘‘sneezing,’’ ‘‘runny nose,’’ ‘‘fatigue,’’ and
‘‘fever.’’ On the other hand, a feature can occur with multiple
diseases. For instance, ‘‘fever’’ occurs not only with the common
cold, but also with hyperthyroidism, leukaemia, rheumatoid
arthritis, and many other infectious and non-infectious diseases.
Thus, there is a complex, many-to-many relationship between
diseases and phenotypic features, which likely reflects the
underlying pleiotropy of biochemical pathways and cellular
networks.
From Gene to Phenotype
Perhaps the most obvious starting point for mapping pheno-
types between species is to investigate animal models with a
mutation in a gene that is orthologous to a human gene associated
with a disease (Figure 1A). Geneticists invoke evolution to bestow a
degree of universality to the function of a gene, inferring that
similarity in the encoded protein sequences implies similarity in
function, and that function is most likely to be conserved between
unique, 1:1 orthologous genes [10,11]. However, the expectation
that an equivalent mutation in an orthologous pair of genes will
yield the same phenotype in two different species fails to
acknowledge the differences that define distinct species. A
phenotype is an often complex and emergent property of a
biological system that is usually influenced directly and indirectly
by many genes. Even for highly penetrant mutations in close and
well-conserved orthologues, significant differences in outcomes
have been observed; neither the disruption of HPRT (Lesch-Nyhan
syndrome) nor mutations in DMD (Duchenne’s muscular dystro-
phy) give strong phenotypes in the mouse [12,13]. Phenotypic
differences may be observed more frequently when comparing
systems, for example, immunity, that are rapidly evolving and/or
subject to large environmental influence, the latter obviously not
well modelled through a laboratory upbringing [14]. However, to
dwell on these differences would be to deliberately ignore the
many more examples of animal models that have yielded
considerable insight into human genetic disease. For instance, at
present, 3,829 mouse models associated to human diseases are
listed in the Mouse Genome Database [15] (http://www.
informatics.jax.org/vocab/omim).
Despite obvious species differences, phenotypic equivalences can
be objectively discovered. The orthologues of genes that function
together in a particular molecular pathway often also function
together in the orthologous pathway in another species even when
separated by a considerable evolutionary distance [16]. As
disruptions to different genes that operate within the same pathway
often produce similar phenotypes [17], disruptions of the ortholo-
gues of genes that yield a given phenotype in human can plausibly
be predicted to yield the equivalent phenotype in a model organism
if they are disrupting the orthologous pathway (Figure 1B).
Marcotte and colleagues systematically demonstrated this
equivalence by forming groups of human genes that shared a
human phenotype and then asking whether there was an unusually
common phenotype amongst any one group’s orthologues in
another species [18]. They termed these evolutionary phenotypic
associations between groups of orthologous genes ‘‘phenologs.’’
The thousands of phenologs discoverable through this approach
included over 150 identified between human and yeast, a
divergence of over 1.5 billion years. Marcotte and colleagues
demonstrated that this objective approach could identify
non-obvious phenologs that were of significant predictive value,
showing, for example, that genes associated with lovastin
sensitivity in yeast, the phenolog of abnormal angiogenesis in
mice, were indeed involved in vasculature formation in Xenopus. In
a similar approach, Webber and colleagues were able to
objectively map phenotypes between human and mouse by
examining the genes affected by mutations in individuals with
neurodevelopmental phenotypes [19,20]. However, while the
phenolog associations revealed by these approaches are often
relevant, they may not be the most specific. For example, while
individuals with psychosis harbour mutations that are enriched in
the orthologues of genes associated with the phenotype abnormal
prepulse inhibition in the mouse, an abnormal prepulse inhibition is
not synonymous with psychosis in humans [21]. The many-to-
many relationship between genes and phenotypes makes the
process of reliably mapping human phenotypes through phenologs
vulnerable to pleiotropic effects and genetic interactions [22].
Perhaps the greatest difficulty in comprehensively mapping
phenotypes lies in the necessary assumption that genes whose
function is not associated with a particular phenotype have been
examined and found not to influence that phenotype: this
assumption is prolifically untrue, with only a fraction of possible
phenotypes examined for only a minority of non-randomly
selected genes, particularly in species such as the mouse and
zebrafish that are less amenable to large-scale screening. To
address this, it would be particularly valuable to identify putative
phenologs in organisms amenable to high-throughput screening
and thereby obtain systematic coverage (see Box 1). However, the
ability to identify equivalent phenotypes between different species
allows one to use genotype-phenotype associations discovered in
one species to infer unexamined associations in another.
Phenotype Ontologies
Other approaches to computational cross-species phenotype
analysis do not begin with the identification of orthologous genes
but rather directly estimate the similarity between phenotypic
abnormalities seen in human disease and animal models.
Ontologies have become an indispensable tool to measure cross-
species phenotypic similarity. An ontology is a representation of
knowledge that uses a controlled vocabulary to enable knowledge
sharing and computer reasoning. ‘‘Ontology’’ was famously
defined as a specification of a conceptualization [23], meaning
that an ontology provides a representation of the concepts of a
domain of knowledge (conceptualization) together with the
semantic relations between them (specification). Ontologies can
be used to represent items of a domain of knowledge, for example,
the Chemical Entities of Biological Interest (ChEBI) ontology
provides a comprehensive representation of biologically relevant
small molecules [24], but also to represent the attributes of domain
concepts. Perhaps the most well-known ontology of this type is the
Gene Ontology [25], which describes the functions, roles, and
locations of gene products. Similarly, phenotype ontologies
describe the phenotypic abnormalities associated with diseases or
found in individual patients or model organisms. In this review, we
will concentrate on the use of the Human Phenotype Ontology
[26,27] (HPO) to describe human genetic disease, and the
Mammalian Phenotype Ontology (MPO) [28,29] to describe
genetically modified mouse models [30]. Each ontology consists of
thousands of terms, each of which represents a single phenotypic
abnormality such as ‘‘atrial septal defect.’’ The terms in the HPO
and MPO are related to one another by subclass (‘‘is a’’) relations,
such that the ontology can be represented as a so-called ‘‘directed
acyclic graph.’’ This structure enables annotation propagation
whereby more specific phenotypic terms are also described by
more general parent terms and, thus, all ancestral terms. For
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instance, if a patient has an abnormality of the cerebellum, he or she can
also be said to have an abnormality of the hindbrain, a term that is an
ancestor of abnormality of the cerebellum (Figure 2).
The phenotypic terms themselves do not describe any specific
disease but may be used to list the phenotypic features that
characterise a particular disease. For instance, to assert that
patients with neurofibromatosis type I have Lisch nodules of the
iris, we annotate the disease neurofibromatosis type I with the
corresponding HPO term, ‘‘Lisch Nodules.’’ Mouse models that
display a given phenotypic abnormality are annotated to MPO
terms in an analogous fashion. The network of diseases, associated
phenotypic features, and genes can now be used for a number of
purposes, including differential diagnostics, prioritization of
candidate genes, and research into the relationships between
genotype and phenotype (Figures 1 and 3).
For some applications, it is sufficient to assert that a given
genetically modified mouse is a good model of some human
disease. For instance, mouse genotypes that have been used to
study specific human diseases are curated by the Mouse Genome
Informatics (MGI) group using disease terms found in the Online
Mendelian Inheritance in Man (OMIM) [31]. While this is useful
to find models for a specific disease, when starting with a set of
Figure 1. Interspecies phenotype mapping strategies. This review highlights three major methodologies to identify phenotypes in the mouse
that are relevant to a human disease. (A) Classical approach. A mouse model is made or identified that possesses a genotype equivalent to a
penetrant mutation that in human underlies the disease of interest (termed construct validity). The mouse model is examined for phenotypes that
resemble those that define the human disorder (face validity). (B) Phenolog mapping. A group is formed containing candidate genes for a disease of
interest. The respective mouse models for the orthologues of these genes are then examined for any unusually overrepresented phenotypes among
them and these phenotypes (termed phenologs) are deemed relevant to the disease. (C) Direct phenotype mapping. Given the phenotype(s) that
describe a human disease, the corresponding phenotypes in mouse are inferred by means of computational reasoning using interspecies phenotype
ontology analysis. In the example shown, the HPO term Aortic stenosis is defined on the basis of the PATO term constricted and aortic valve (term from
the Foundational Model of Anatomy ontology of human anatomy [35]). Similarly, the MPO term aortic valve stenosis is defined using the same PATO
term constricted and aortic valve (term from the Mouse Anatomy ontology [77]). Since both the Mouse Anatomy and FMA terms for aortic valve are
children of the cross-species anatomy ontology (Uberon [40]) term for aortic valve, automatic reasoning places the HPO term Aortic stenosis and the
MPO term aortic valve stenosis in the direct vicinity of one another in a cross-species phenotype ontology [42]. Therefore, these terms display a high
semantic similarity to one another.
doi:10.1371/journal.pgen.1004268.g001
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observed phenotypes the relations described in the HPO or MPO
allow us to identify all diseases (or models) characterised by those
phenotypic features. Similarly, by identifying equivalent pheno-
types between the HPO and the MPO, a search would be able to
return both relevant mouse models and relevant human diseases.
In addition to phenolog mapping described above, another
approach to creating phenotypic equivalences might be to
manually assign phenotype terms from one ontology to the other.
For instance, one could assert that the MPO term hypoglycemia
(MP:0000189) is equivalent to the HPO term Hypoglycemia
(HP:0001943). While this particular mapping seems perfectly
reasonable, it is not possible to map every individual term in one
ontology to the equivalent term in the other ontology; many
individual phenotypic features do not have a clear match in the
other species, and the way a phenotype is observed and recorded
in mice is often quite distinct from phenotypic analysis performed
in the course of a medical examination. For instance, there is no
obvious match in humans for the MPO term abnormal tail movements
(MP:0001391), and there is no obvious match in mice for the HPO
term Expressive language delay (HP: 0002474). Another important
issue is that phenotypes elicited in the course of scientific
experiments on mouse models are not equivalent to medical
phenotypes. For instance, it is not uncommon to subject mouse
hearts to ischemia and reperfusion to induce cardiac damage, and
then to compare the hearts of mice with a certain genetic defect to
those of wild-type mice. If the mutant mice exhibit larger
infarctions than the wild-type mice, the MPO term increased
myocardial infarction size (MP:0003037) is used to annotate them.
Obviously, there is no corresponding HPO term, and in fact it is
not even entirely clear what the relationship of increased myocardial
infarction size to the HPO term Myocardial infarction should be.
For this reason, a different strategy was chosen to develop
semantic mappings between the HPO and the MPO. A crucial
part of this strategy is the use of logical definitions to enable
sophisticated semantic reasoning over ontology terms. Logical
definitions of phenotype terms use building block ontologies to
represent the various anatomical, cellular, physiological, and
metabolic abnormalities, combining them into ontology classes
using semantic constructs of the ontology language OWL. The
Phenotype, Attribute, and Trait Ontology (PATO) is a key tool in
this effort because it provides an abstract representation of the
abnormal qualities encountered in the phenotypic abnormalities
(Figure 1C) [32–34]. PATO consists of a single hierarchy of
qualities designed to be used in conjunction with other ontologies
representing entities that are the bearers of abnormal phenotypic
qualities, including the Foundational Model of Anatomy (FMA)
ontology [35], the Gene Ontology (GO) [36], and the cell ontology
[37]. Many phenotype terms can be defined using the Entity/
Box 1. Comparing Phenotypes with More Distant Species.
This review has concentrated on interspecies ontology
analysis of mouse, the model organism with the highest
number of genes orthologous to human and the highest
number of explicit models for distinct human diseases.
However, while mouse models of disease often appear to
most resemble their human counterparts, other model
organisms offer important advantages for studying specific
areas of physiology and disease-related biology. For exam-
ple, the zebrafish is particularly amenable to understanding
early development, due to the externally developing,
transparent embryos and ease of molecular perturbation.
Large-scale screens of the fruit fly Drosophila melanogaster,
the zebrafish Danio rerio, and the nematode worm
Caenorhabditis elegans mutants have been performed for
several decades, and a large and diverse amount of
phenotypic information has been collected. These data,
while inclined towards the specific beneficial features of each
model system, are complementary to one another and to
mouse in their scope. Furthermore, unlike with mouse, they
tend not to be as biased towards the investigation of a
specific disease, as is often the case for mouse studies. The
nematode worm C. elegans is used as a model to study
cellular differentiation and basic biological processes, with
the developmental fate of each of its up-to1,031 somatic
cells having been mapped. The relative ease of genetic
manipulation in C. elegans by techniques such as RNA
interference [80] has enabled large-scale and largely unbi-
ased investigations of the phenotypic consequences of
alterations of gene function, and over 420,000 Worm
Phenotype Ontology (WPO) annotations are available from
the Wormbase [81]. Similarly, the fruit fly Drosophila is one of
the most widely used model organisms in genetics since
Thomas Hunt Morgan’s discovery of chromosomes as the
carriers of genes in D. melanogaster. Currently, over 358,000
phenotype annotations are available in the model organism
database for Drosophila genetics, Flybase [82].
To support annotation and analysis of these models, many
model organism consortia are developing phenotype
ontologies that are amenable to the kind of cross-species
semantic analysis described in this review, because of their
use of modular definitions that make use of existing
ontologies from the Open Biological Ontology (OBO)
Foundry initiative [41] as building blocks. Depending on
the species in question, building block ontologies repre-
senting anatomy, pathology, gene function, embryology,
biochemistry, and others are used to provide computational
definitions of phenotypic abnormalities. Interoperable phe-
notype ontologies and annotations are thus now available
for human [26], mouse [29], zebrafish [75], nematode worm
C. elegans [81,83], fruit fly Drosophila [84], rat [85], and fission
yeast [86]. However, one of the issues is that the nature of
the genotype-phenotype annotations in each of these
sources differs. In one source, the phenotypes are linked to
an allele or gene, whereas in another they might be linked to
a full genotype. Furthermore, since the ontologies were
constructed independently and according to different
principles or focus, relating them requires some sophisticat-
ed ontological engineering techniques [40]. Interoperation of
these ontologies and the genotype-phenotype annotations
is a primary goal of the Monarch Initiative (monarchinitiati-
ve.org), which provides integrated data and phenotype
comparison analysis resources that are available to the
community. Inclusion of these diverse phenotype data bring
the phenotype coverage up to approximately 80% of human
genes based on orthology, which may be beneficial for the
identification of rare and undiagnosed genetic disease
causes. Additionally, other efforts such as the Phenotype
Ontology Research Coordination Network (RCN) [87] are
aiming to develop standards and best practices for accurate
phenotype representations across a range of plants, verte-
brates, and arthropods for evolutionary biology. In the
future, it will be important to improve computational
methodologies for phenotypic analysis over a large range
of species to make best use of the advantages that each
model organism has to offer.
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Quality paradigm. In the following example, we consider an HPO
term that describes increased width of the big toe.
Class: HP:0010055
Annotations: label ‘‘Broad hallux’’
EquivalentClassOf:
has_part some:
increased width (PATO_0000600) and
inheres_in some Big toe FMA:25047
That is, the HPO class ‘‘Broad hallux’’ is defined as being
equivalent to a phenotype of increased width that inheres in (is located in)
a Big toe. Many phenotype terms require more complicated definitions
that include references to multiple domain ontologies. For instance,
the following definition of the HPO term Hyperalaninemia uses
references both to the FMA term for blood and to ChEBI for alanine.
Class: HP: 0003348
Annotations: label ‘‘Hyperalaninemia’’
EquivalentClassOf:
has_part some:
increased concentration (PATO:0001162) and
inheres_in Portion of blood (FMA:9670) and
towards alanine (CHEBI:16449)
These definitions enable interoperability of the HPO with the
other ontologies in the sense that it becomes possible to search for
all phenotype terms that involve entities from one of the domain
ontologies, comprising not only anatomy and small molecules as
shown above, but also gene function [36], cell types [37], proteins
[38], pathology [39], and others. Also, thanks to Uberon, an
integrated cross-species ontology, it is possible to map anatomical
terms across species [40]. Thus, by using logical definitions for
mouse and human phenotypes that have been developed using
interoperable ontologies from the Open Biomedical Ontology
(OBO) Foundry [41], a common computational basis is created
that in turn makes it possible to identify equivalent or similar terms
between phenotype ontologies for different species by using
automatic reasoning [42–44].
A number of different approaches to interspecies phenotype
mapping have been applied by several groups, and we will refer to
the original publications for algorithmic details [32,43,45–47].
However, for the most part the algorithms make use of logical
definitions as shown above to identify equivalencies or similarities
between terms of phenotype ontologies for two or more species
(Figure 1C). Each animal disease model or human disease is then
annotated to one or more ontology terms. For instance, the human
disease Marfan syndrome is annotated to a number of HPO terms
including Tall stature (HP:0000098), Kyphoscoliosis (HP:0002751),
Ectopia lentis (HP:0001083), and Aortic root dilatation (HP:0002616).
The mgR mouse model of Marfan syndrome [48] is annotated to a
number of MPO terms including increased length of long bones
(MP:0004695), which is similar to the HPO term Tall stature (which
in Marfan syndrome results from overgrowth of the long bones);
kyphosis (MP:0000160), which is similar to the HPO term
Kyphoscoliosis; and aortic aneurysm (MP:0006278), which is similar
to the HPO term Aortic root dilatation (an aneurysm is a protruding
sac formed by the dilation of the wall of the aorta, whereas the
term Aortic root dilatation refers to an increase in the diameter of the
proximal section of the aorta). The mgR model does not display an
ocular phenotype, so there is no obvious match for the HPO term
Ectopia lentis (a dislocation of the lens of the eye). To calculate a
phenotypic similarity between the human disease and the mouse
model, the algorithms mentioned above search over each of the
terms of the human disease and look for the best match amongst
the terms used to annotate the mouse model and vice versa. The
sum of the similarities, which are usually expressed using their
information content, is then used as a measure of the similarity
between the diseases. The information content is calculated based
on the frequency with which a given ontology term is used to
annotate diseases in a database and thereby provides a way of
weighting the matches based on the specificity of the phenotypic
features: the less specific a phenotype is, the lower the information
content. Many algorithms have been presented to calculate this
kind of semantic similarity with ontologies, and the field represents
an area of active research in bioinformatics [49]. Another recent
Figure 2. Phenotype ontologies. Phenotype ontologies (an excerpt
from the Human Phenotype Ontology is shown here) consist of
thousands of terms describing phenotypes arranged in a hierarchical
system of subclasses and superclasses. The structure of an ontology
enables annotation propagation whereby more specific phenotypic
terms are also described by more general parent terms, and thus all
ancestral terms. The terms are related to one another by subclass (‘‘is
a’’) relations, such that the ontology can be represented as a so-called
directed acyclic graph. The terms themselves do not describe any
specific disease. Instead, annotations to terms are used to state that a
certain disease is characterised by a certain phenotypic feature.
doi:10.1371/journal.pgen.1004268.g002
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approach to the use of ontologies for differential diagnostics in
human medicine did not rely on semantic similarity algorithms but
rather embedded the HPO and the diseases annotated to terms of
the HPO into a Bayesian network, thereby providing a principled
framework to deal with noise in phenotypic data and demonstrating
a substantially improved performance on simulated data [50].
Although the field of semantic phenotype matching is still in its
infancy, even now mouse data are demonstrably better at
identifying genes that influence the same human phenotypes than
other commonly used gene annotations such as Gene Ontology or
Kyoto Encyclopaedia of Genes and Genomes (KEGG) (Figure 3).
Robinson and colleagues have also recently shown that cross-species
phenotype matching is a powerful method for the prioritization of
candidate genes in whole-exome sequencing studies [51].
Cross-Species Analysis of Behavioural
Phenotypes and Elucidating the Genetic
Architecture of Psychiatric Disease
Behavioural disorders, notably psychiatric disorders, present a
particularly difficult challenge to both phenotype ontologies and
cross-species analysis. For example, determining the presence in a
mouse model of any of the new Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition (DSM V) positive symptoms
required in the diagnosis of schizophrenia (‘‘hallucinations,’’
‘‘delusions,’’ or ‘‘disorganised speech’’) is clearly problematic
[52]. Furthermore, current psychiatric diagnostic classifications
similarly label patients presenting with a broad spectrum of
phenotypes, and heterogeneous presentations likely result from
heterogeneous aetiologies. However, given a well-characterised
and large cohort of patients harbouring likely highly penetrant
mutations, relevant mouse model phenotypes can still be
objectively discovered: considering genes affected by de novo
copy-number variations in 186 individuals with autism, Webber
and colleagues were able to associate over 40 phenologs which
were well correlated to the phenotypes already observed in existing
mouse models of autism-associated genes [53]. However, while the
association identified between autism and the mouse phenotype
stereotypic behaviour is readily comparable to the autistic phenotype
of repetitive behaviours and interests, there were no clear and specific
associations to the impaired social interaction and verbal and non-
verbal communication deficits that also define autism [54].
Results of genome-wide association studies (GWAS) suggest that
current approaches to the diagnosis and classification of psychi-
atric diseases are inadequate. For instance, GWAS findings have
challenged the traditional distinction between schizophrenia and
bipolar disorder by identifying genes such as CACNA1C that
harbour risk alleles for both disorders [55]. Such findings did not,
perhaps, come as a complete surprise given the fact that relatives
of probands with either disorder have increased risks of both
schizophrenia and bipolar disorder [56], as well as the well-known
clinical overlap between the two: patients with bipolar disorder
can have episodes of psychosis during either manic or depressed
phases. In fact, more recent findings show that specific single
nucleotide polymorphisms can be associated with a range of
psychiatric disorders of childhood or adult onset [57].
We join with others to suggest that it may be beneficial to take a
new approach to the analysis of neurobehavioural disorders that
will focus on the individual components of the disorder rather than
just the final diagnostic category [58]. This new approach has two
potential benefits. While the main clinical purpose of a diagnostic
category is to allow therapeutic and prognostic decision making, it
is arguable that the most useful clinical categories, phenotypic
features, dimensional definitions, and measures for psychiatric
disease are still unknown [55]. Therefore, the act of reducing
probably heterogeneous groups of patients to a single clinical
category such as bipolar disorder is likely to reduce the power of
GWAS or sequencing studies to elucidate the molecular pathology
of psychiatric disease. Studies based on richer representations of
the phenotype may, in contrast, allow new hypotheses to be tested,
such as that a certain genetic variant is a risk factor for psychosis,
rather than schizophrenia or bipolar disorder per se [59].
The second potential benefit of this approach for neurobehav-
ioral clinical research is an improved ability to make use of animal
models to understand psychiatric disease by allowing more
accurate interspecies phenotypic comparisons on the basis of
individual phenotypic aspects of a disorder rather than on complex
emergent phenomena associated with a disorder. For instance,
glucocorticoids influence neuronal function in the brain, and are
thought to be involved in the onset of depression when levels are
abnormally high [60]. However, it is still unclear how glucocor-
ticoid signalling is linked to affective disorders. A zebrafish mutant
with a mutation in the glucocorticoid receptor was shown to
become immobile (‘‘freeze’’) and to show reduced exploratory
behaviour when placed into an unfamiliar aquarium (‘‘novel
Figure 3. Predicting human genotype-phenotype relations
from functional genomics data. The mouse phenotypes associated
with the orthologues of human genes are a better predictor of genes
that share human phenotypes than other popular gene annotations of
the same genes, such as GO or KEGG. As both GO and KEGG include
information derived from multiple sources, including annotations from
the mouse, the success of the mouse phenotypes is likely due both to
the genetic relevance of the mouse models and the fact that human
and mouse phenotypic annotations both describe abnormalities (see
Figure 1C). Resnik’s [78] measure, together with the GraSM approach
[79], was used to calculate the similarity of terms organised in these
hierarchical ontologies, defining the semantic similarity between any
two terms as the average information content of their disjunct
common-ancestor terms. Gene pairs were ordered by their semantic
similarity scores based on either the human KEGG pathway annotations
(pink circles), human GO biological process (grey circles), or MPO
annotations to genes (blue circles). For each of KEGG, GO, and MPO
annotations, gene pairs were ordered in decreasing annotation
similarity and grouped into bins of 2,000, and then the median
semantic similarity score between gene pairs’ Human Phenotype
Ontology annotations was calculated. The dashed line marks the
degree of similarity expected from pairs of random genes.
doi:10.1371/journal.pgen.1004268.g003
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tank’’), abnormalities that could be reversed by the addition of the
antidepressant fluoxetine to the holding water [61]. While it
appears quite reasonable to infer that this zebrafish is modelling
some aspect of depressive psychopathology, it is presumably not a
faithful model of any specific human disorder, such as major
depressive disorder, with symptoms such as feelings of excessive or
inappropriate guilt or suicidal ideation.
The above considerations fit well with the so-called endophe-
notype concept in psychiatric genetics. An endophenotype in
psychiatry refers to an internal process that can be objectively
measured. An endophenotype is an individual feature that may be
a component of a psychiatric disease. Psychiatric endophenotypes
are defined as being heritable features that tend to manifest in
individuals with psychiatric diseases whether or not the disease
itself is active, and that not only cosegregate in families together
with the disease but also tend to be found in unaffected relatives of
an individual with a psychiatric disease at a higher rate than in the
general population [62]. One main reason why endophenotypes
have attracted attention is the assumption that if an endopheno-
type represents a more or less atomic component of a complex
disease entity, then the number of genes required to produce
variations in these traits may be fewer than those involved in
producing a psychiatric diagnostic entity, making it easier to
identify genetic factors for endophenotypes than for disease entities
[63]. Although a meta-analysis published in 2007, i.e., before the
publication of large-scale psychiatric GWAS, failed to show an
advantage for the analysis of endophenotypes in the identification
of risk alleles for schizophrenia [62], more recent results have
identified loci significantly associated with various endophenotypes
in schizophrenia [64,65]. However, it should not necessarily be
assumed that endophenotypes themselves have a simpler genetic
architecture than psychiatric illnesses. Additionally, what appears
to be an equivalent endophenotype in human and mouse may
actually reflect a different pathophysiology. For instance, deficits in
mouse spatial working memory have recently been reported to be
based in the hippocampus, questioning the face validity of this
phenotype for deficits in working memory associated with scz/bpd
in humans, the latter based in the frontal cortex [66]. That said, in
many cases genetically altered mice do seem to provide valid
models for aspects of human psychiatric diseases. For instance,
schizophrenic patients report oversensitivity to sensory stimulation
that possibly could be related to the cognitive fragmentation seen
in this disorder. Experiments with cortical event-related potentials
and the prepulse inhibition of startle responses have shown that
schizophrenic patients also have impaired central nervous system
inhibition (sensorimotor gating) [67]. Correspondingly, neuregulin
1 (NRG1) is a schizophrenia susceptibility gene in humans, and
mice lacking any one of the several isoforms of Nrg1 display deficits
in sensorimotor gating [68], among other abnormalities that
resemble some of the features of human schizophrenia. Similarly,
the SNAP25 gene has been linked to schizophrenia in association
studies [69], and mouse models with abnormalities in SNAP25
have been shown to have abnormalities in rest and activity
rhythms, reminiscent of the disturbed sleep patterns observed in
schizophrenia [70]. Therefore, if appropriate caution is exercised
in the interpretation of results, a case can be made that it may be
simpler to investigate the genetic correlates of psychiatric
endophenotypes in mouse models. Indeed, analogous touch-screen
tests performed by humans and by mice, both carrying mutations
in DLG2, a gene implicated in schizophrenia, have demonstrated
comparable cognitive impairments, illustrating that endopheno-
types can be much more directly and readily equated between
species [71]. It has been proposed that one way of improving our
understanding of the underlying molecular mechanisms of
neurobehavioural diseases such as schizophrenia lies in the
statistical cross-comparison of datasets arising from analyses of
animal models and human studies, which will identify experimen-
tal and clinical biomarkers. Such findings would lend credibility to
the animal models and could potentially be used to monitor
treatment effects in these models [72]. To achieve this goal, we
suggest that targeted work on developing comprehensive and
consistent ontological representations of the neurobehavioral
phenotypes in humans, mice, and zebrafish would be quite
valuable.
Conclusions
The human genome project was compared by Victor McKusick
to the anatomical atlas of Vesalius published in 1543, in that both
works provided for the first time a comprehensive list of parts that
the human body (or genome) contains, but did not actually explain
how the parts work together to mediate function. William Harvey
capitalised on the knowledge contained in the Vesalius atlas to
describe the basic principles of the circulation 85 years after the
publication of the atlas [73]. Similarly, the challenge for the
coming decades will be to assign physiological functions and
medical roles to the parts of the genomic atlas and to begin to
understand how the parts fit together into larger systems. Current
large-scale projects, including the International Mouse Phenotyp-
ing Consortium [74] and the ever-growing amount of data being
organised by resources such as the Zebrafish Model Organism
Database [75], stand to play a transformative role in this effort by
providing a comprehensive view of the phenotypic consequences
of the majority of protein-coding genes in the vertebrate and
mammalian repertoire. Similar resources are being developed for
the investigation of microRNA genes [76], and it is a good bet that
regulatory sequences such as tissue-specific enhancers will be next
in line. Computational analysis of the phenotype will play a critical
role in these efforts. In this review, we have highlighted a number
of computational resources and algorithms that have been
developed to address current challenges in the field, but it seems
fair to say that the field of computational phenotype analysis is still
in its infancy. Nonetheless, computational interspecies phenotype
analysis will play a crucial role to make full use of the data
emerging from large-scale projects, such as the International
Mouse Phenotyping Consortium and the Zebrafish Mutation
Project, that stand to translate the genomic atlas into functional
and medical discoveries that will improve our ability to treat
human disease.
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